Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics Inc.

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics today and set a price target of $130.00. Slutsky covers the He...

Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital

Chardan Capital analyst Geulah Livshits maintained a Buy rating on Palvella Therapeutics yesterday and set a price target of $110.00. Livshits cove...

Current Quarter	$-0.95	Next Quarter	$-0.87
Current Year	$-3.46	Next Year	$-3.64
QoQ Growth	+8.4%	YoY Growth	-5.2%
3Y EPS CAGR	-122.6%	Target Price	$113.75
Consensus	Buy	Upside	+20.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$94.09	+2.79%	232.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$94.09	+2.8%	232.88K
3
4
5
6

PVLA

PVLA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Palvella Therapeutics Inc. Data in Excel

Get Palvella Therapeutics Inc. Data in Excel